Drug intelligence / Profile preview

T-BioVax

Development stage: Preclinical
Lead developer: ImmunoBiology
Modality: Vaccines & Immunotherapeutics

Overview

T-BioVax is an investigational tuberculosis vaccine being developed by ImmBio as a prophylactic immunotherapy against infection with Mycobacterium tuberculosis. Publicly available information indicates it is a vaccine candidate referred to as “T-BioVax vaccine against TB infection,” but detailed data on its construct, antigen composition, adjuvant system, or exact mechanism of action have not been disclosed. The program appears to be at a preclinical or very early clinical stage, with limited technical information in the public domain, and no clear evidence yet of regulatory approval or advanced-stage trials.

Beyond the preview

Go deeper on T-BioVax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-BioVax.

Explore the full profile